Get the Stockscreener App
6.09
2.35%
0.14
Coya Therapeutics Inc stock is traded at $6.09, with a volume of 39,841.
It is up +2.35% in the last 24 hours and up +6.84% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$5.95
Open:
$6.21
24h Volume:
39,841
Relative Volume:
0.67
Market Cap:
$101.86M
Revenue:
-
Net Income/Loss:
$-14.88M
P/E Ratio:
-6.2143
EPS:
-0.98
Net Cash Flow:
$-10.29M
1W Performance:
-8.70%
1M Performance:
+6.84%
6M Performance:
+0.16%
1Y Performance:
-9.64%
1-Day Range:
$5.8715
$6.21
1-Week Range:
$5.7513
$6.84
52-Week Range:
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
6.09 | 99.51M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
Should you wait for a breakout in Coya Therapeutics Inc.Free Top Gaining Picks With Entry Signals - Newser
Is Coya Therapeutics Inc. stock ready for a breakoutTrend Confirmation Scanner with Entry Focus - Newser
Using Python tools to backtest Coya Therapeutics Inc. strategiesMachine Learning Stock Price Forecast Tool - Newser
Why Coya Therapeutics Inc. stock attracts strong analyst attentionTrade Safety Matrix for Conservative Traders - Newser
Strategies to average down on Coya Therapeutics Inc.Chart Based Entry Tool for ROI Traders - Newser
How to manage a losing position in Coya Therapeutics Inc.Intraday Strategy with Real Time Monitoring - Newser
Sector ETF performance correlation with Coya Therapeutics Inc.High Return Trade Roadmap with Setup Filters - Newser
Applying Wyckoff theory to Coya Therapeutics Inc. stockFree AI Screening for Swing Trade Picks - Newser
How many analysts rate Coya Therapeutics Inc. as a “Buy”Stock Strategy Alerts For Consistent Profits - jammulinksnews.com
Is Coya Therapeutics Inc. stock overvalued or undervaluedTop Growth Forecasts Backed By Experts - jammulinksnews.com
Price action breakdown for Coya Therapeutics Inc.Free Fundamental Winners With Safe Entry Plan - Newser
How strong is Coya Therapeutics Inc. company’s balance sheetTop Growth Tips For Consistent Profits - jammulinksnews.com
Published on: 2025-07-31 11:13:46 - metal.it
Published on: 2025-07-30 21:39:20 - Newser
Merck to discontinue drug from Pandion deal; Coya’s IND for ALS drug is delayed - Endpoints News
Buy Signal for Coya Therapeutics Inc. Stock Key Technical Indicators to WatchROI Focused Setup With Drawdown Analysis - Newser
Coya Therapeutics IncFDA unable to meet review goal date for Coya's IND for phase 2 ALS studySEC filing - MarketScreener
How Resilient Is Coya Therapeutics Inc. Stock During Economic DownturnsDaily Chart Pattern Stock Forecast Shows Bullish Setup - metal.it
What makes Coya Therapeutics Inc. stock price move sharplyFree Weekly Return Pick Forecast Reports - Newser
What is Coya Therapeutics Inc. company’s growth strategyStock Strategy Insights For Consistent Profits - jammulinksnews.com
Is it the right time to buy Coya Therapeutics Inc. stockRetirement Planning Updates For Consistent Profits - jammulinksnews.com
Coya Therapeutics Inc. Stock Performance After Earnings: Historical Insights3-Year Equity Summary With Setup Insights - Newser
Why Coya Therapeutics Inc. stock attracts strong analyst attention Sector Rotation and Stock Opportunity Analysis - Newser
How volatile is Coya Therapeutics Inc. stock compared to the marketDiscover high-impact stocks for growth - jammulinksnews.com
How does Coya Therapeutics Inc. compare to its industry peersStrong return on assets - jammulinksnews.com
When is Coya Therapeutics Inc. stock expected to show significant growthInvest confidently with professional advice - jammulinksnews.com
What are the technical indicators suggesting about Coya Therapeutics Inc.Build a diversified portfolio for risk mitigation - jammulinksnews.com
Intrinsic Value of Coya Therapeutics Inc. Stock: Is It Undervalued or OvervaluedStrategic High Profit Opportunities - Newser
Coya Therapeutics Inc. Company Revenue and Profit Trends: A Deep DiveFree Day Trading Recommendations - Newser
How Coya Therapeutics Inc. stock performs during market volatilityOptimized Return Investment Picks - Newser
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Coya Therapeutics Inc Stock (COYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):